Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 27658693.
- Also identified by PMC identifier 11264234.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is limited information on antiviral therapy for hepatitis B virus (HBV) infection among pregnant women coinfected with human immunodeficiency virus (HIV) and HBV. A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China. The HBV virological response was compared in study arms. The median decline in the HBV DNA level was 2.60 log<sub>10</sub> copies/mL in the TDF/3TC arm and 2.24 log<sub>10</sub> copies/mL in the 3TC arm (P = .41). All women achieved HBV DNA levels of <6 log<sub>10</sub> copies/mL at delivery. Initiation of either regimen led to achievement of HBV DNA levels below the threshold associated with perinatal HBV transmission. NCT01125696.
Medical subject headings
- Antiviral Agents
- HIV Infections
- Hepatitis B
- Lamivudine
- Pregnancy Complications, Infectious
- Tenofovir
- Viral Load